topstockalerts
Sep 15, 1:51 AM
Kestra Medical Technologies reported fiscal Q1 2027 results after the market close, posting an adjusted loss of
$0.75 per share for the quarter ended July 31, 2026, significantly worse than the
$0.63 consensus estimate and wider than the
$0.50 loss a year earlier. Revenue rose 60% year over year to
$31.0 million, while gross margin expanded to 56.5% from 45.7%, and management raised its FY2027 revenue forecast to
$141 million from
$137 million, implying 48% growth from FY2026.
However, GAAP net loss widened sharply to
$44.1 million from
$25.8 million, while adjusted EBITDA loss deepened to
$24.0 million, raising concerns about the company’s path to profitability. Insider selling has also been heavily skewed, with 37 open-market sales versus just one purchase over the past six months. Short interest has climbed to nearly 11% of the public float, adding further downside pressure.
$KMTS
